Survival of Lung Transplant Patients With Cystic Fibrosis Harboring Panresistant Bacteria Other Than Burkholderia cepacia, Compared With Patients Harboring Sensitive Bacteria

Journal of Heart and Lung Transplantation

Volumn 26, Issue 8, 2007, Pages 834-838

  Hadjiliadis, Denis ^a   Steele, Mark P ^b   Chaparro, Cecilia ^c   Singer, Lianne G ^c   Waddell, Thomas K ^c   Hutcheon, Michael A ^c   Davis, Robert D ^b   Tullis, Diana E ^d   Palmer, Scott M ^b   Keshavjee, Shaf ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DUKE UNIVERSITY   (United States)

^c Toronto Lung Transplant Program   (Canada)

^d Toronto Adult Cystic Fibrosis Program   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZATHIOPRINE; CARBAPENEM; CEPHALOSPORIN; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLIN G; PREDNISONE; QUINOLONE; TACROLIMUS; TOBRAMYCIN;

ACHROMOBACTER XYLOSOXIDANS; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; BURKHOLDERIA CEPACIA; CONTROLLED STUDY; CYSTIC FIBROSIS; DATA ANALYSIS; DRUG SENSITIVITY; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; LOG RANK TEST; LUNG INFECTION; LUNG TRANSPLANTATION; MALE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REGISTER; RETROSPECTIVE STUDY; STENOTROPHOMONAS MALTOPHILIA; SURVIVAL RATE; UNIVERSITY HOSPITAL;

ADULT; ANTI-BACTERIAL AGENTS; BURKHOLDERIA CEPACIA; BURKHOLDERIA INFECTIONS; COLONY COUNT, MICROBIAL; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; LUNG TRANSPLANTATION; MALE; NORTH CAROLINA; ONTARIO; RISK FACTORS; SURVIVAL RATE;

EID: 34547607076     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.05.018     Document Type: Article

References (22)

1. Orenstein D.M., Rosenstein B.J., and Stern R.C. Transplantation. Cystic fibrosis medical care (2000), Lippincott Williams & Wilkins, Philadelphia 229-254
2. Cystic Fibrosis Foundation patient registry report: 2004 annual data report (2005), Cystic Fibrosis Foundation, Bethesda, MD
3. Trulock E.P., Edwards L.B., Taylor D.O., Boucek M.M., Keck B.M., and Hertz M.I. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report-2006. J Heart Lung Transplant 25 (2006) 880-892
4. Hosenpud J.D., Bennett L.E., Keck B.M., Edwards E.B., and Novick R.J. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 35 (1998) 24-27
5. Chapman S.C., Sharples L.D., McNeil K.D., and Wallwork J. Assessment of survival benefit after lung transplantation by patient diagnosis. J Heart Lung Transplant 21 (2002) 226-232
6. DeMeester J., Smits J.M.A., Persijn G.G., and Haverich A. Listing for lung transplantation: life expectancy and transplant effect, stratified by type of end-stage lung disease, the Eurotransplant experience. J Heart Lung Transplant 20 (2001) 518-524
7. Liou T.G., Adler F.R., Cahill B.C., et al. Survival effect of lung transplantation among patients with cystic fibrosis. JAMA 286 (2001) 2683-2689
8. Chaparro C., Maurer J., Gutierrez C., et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 163 (2001) 43-48
9. Aris R.M., Routh J.C., LiPuma J.J., Heath D.G., and Gilligan P.H. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 164 (2001) 2102-2106
10. Griffith B., Hardesty R., Armitage J., et al. A decade of lung transplantation. Ann Surg 218 (1993) 310-320
11. Aris R.M., Gilligan P.H., Neuringer I.P., Gott K.K., Rea J., and Yankaskas J.R. The effect of panresistant bacteria in cystic fibrosis patients on lung transplantation outcome. Am J Respir Crit Care Med 155 (1997) 1699-1704
12. Dobbin C., Maley M., Harkness J., et al. The impact of pan-resistant bacterial pathogens on survival after lung transplantationin cystic fibrosis: results from a single large referral centre. J Hosp Infect 56 (2004) 277-282
13. McNeil K., Glanville A.R., Wahlers T., et al. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation 81 (2006) 998-1003
14. Kesten S., and Chaparro C. Mycobacterial infections in lung transplant recipients. Chest 115 (1999) 741-745
15. Palmer S.M., Perfect J.R., Howell D.N., et al. Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents. J Heart Lung Transplant 17 (1998) 1029-1033
16. Palmer S.M., Miralles A.P., Lawrence C.M., Gaynor J.W., Davis R.D., and Tapson V.F. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest 116 (1999) 127-133
17. Palmer S.M., Baz M.A., Sanders L., et al. Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation 71 (2001) 1772-1776
18. Hadjiliadis D., Howell D.N., Davis R.D., et al. Anastomotic infections in lung transplant recipients. Ann Transplant 5 (2000) 13-19
19. National Committee on Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing (2007) Document M100-S17. 27
20. Allison P.D. Survival analysis using the SAS system: a practical guide (1995), SAS Institute, Cary, NC
21. Aaron S., Vandemheen K.L., Ferris W., et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 366 (2005) 463-471
22. Hadjiliadis D., Edwards L.B., and Keshavjee S. Effect of transplant center volume on survival after lung transplantation stratified by diagnosis. Am J Respir Crit Care Med 169 suppl (2004) A504